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• Vaccines:  the Research and Development Process
• Development & Testing of a DNA-based COVID-19 Vaccine
• How epidemiology is involved in the pharma R&D process 
for vaccines
• Time permitting: information on therapeutic R & D, great vaccinologists, etc.
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Vaccines:  the Research and 
Development Process
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Vaccines:  the Research and Development Process
• In normal circumstances, prepare for 12 to 14 years and about $1 billion to completion, i.e. to regulatory 
approval and marketing initiation…
• For an extreme epidemic or pandemic situation, have already in place a) a vaccine rapid development 
platform, b) manufacturing scale-up/funds – then, when the epidemic/pandemic begins, initiate R & D as 
rapidly as possible and pursue regulatory approval pathways that allow for more rapid review & approval 
– and, collaborations are critical
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process:  Very high-level – many sub-steps & sub-sub steps are not shown …
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 1:  Pick a condition or disease
Disease “X”   OR  Disease “Y”   OR   Disease “Z” …
• How many people have the disease now?
• How many people acquire it each year?
• How severe is the disease?  Can it cause 
death?
• Is there a treatment available?  If so, 
how effective and costly is it?
• etc., etc., etc. ...
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 2: Invent (discover) the vaccine construct & estimate the POS
• Is an invention already available?  If so, e.g. was is tried before and 
failed?
• If tried before and failed, is there 
some evidence or plausibility and 
adjustment might render it 
workable?
• If no invention already available, is 
there reason to believe some 
technique would allow an invention 
to be made?
• Probability Of Success (POS) = How 
likely would an old or new invention of 
interest work?  Is that likelihood acceptable given the occurrence and 
severity etc. of the disease and the available resources?
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 3: Test it pre-clinically
• Cellular or similar experiments in petri dishes etc. in the lab
• Then to small rodent animal models – for safety and early 
signs of intended effect SAFETY 
FIRST!
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 4: Test it pre-clinically again…
• Larger rodent animal models
• Primate animal models




Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 5:  Revise the invention as needed
• How well did the vaccine “candidate” 
(or usually many candidates tested)
work in the pre-clinical testing?
• Are changes possible that could make the candidate 
vaccine(s) better?  (i.e. safer and/or with better effect)
• If so, implement those changes and go back to pre-clinical 
testing again if needed …
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 6:  Test it clinically:  Phase I
• First in Human (FIH) testing:  very small 
clinical trial, e.g. 10 to 40 persons, who 
are volunteers and almost always healthy 
young adults
• The phase I trial focuses primarily on safety, 
and it is often staggered in terms of sequential 
administration in different volunteers and doses
• The volunteers sometimes stay full time (day and night) in a 
secure, controlled facility, where they are observed very 
extensively by medical staff and given many medical tests to detect 
any sign of safety issues (e.g. blood and urine drawn, EKGs, imaging, 
etc.)
• These trials often also assess indirect, early evidence for 
intended effect (e.g. immunogenicity)
19
Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 7: Manufacture a large amount of the vaccine
• Manufacturing is an extremely well-controlled process, with 
many tests and repeated (redundant) tests, to ensure purity, 
non-contamination, and potency of the product
• Much record keeping
• Much review by the manufacturer
• Inspections and evaluations by the FDA etc.
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 8: Test it clinically: Phase II  (POC)
• Proof of Concept (POC) – defined: 
Clinical Effect, etc.
• Pull out $$$$!
• This is a larger clinical trial than phase I, e.g. 50 to 500 
volunteers, and has a more complex “design” – e.g. vaccine 
versus a “placebo” – and is often blinded or double-blinded





Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 9:  Test it clinically: Phase III  (& again…)
• A phase III clinical trial is often called a “pivotal” or 
“registration” trial (i.e. pivot from a controlled, clinical trial setting to 
later use on the full market
• This trial is much, much larger than 
phase I trials and much larger than 
phase II trials – (e.g. several hundred
to many thousands of patients)
• Safety is still a focus, but the additional focus on efficacy is now 
expanded to be confirmatory




Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then….
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Vaccines R & D, cont’d.
Step 10: Apply for and receive regulatory approval
• A long and very involved process
• This is the BIG decision by FDA 
in the U.S. (and other regulatory 
agencies for other countries)
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Vaccines:  the Research and Development Process, cont’d.
• 10-step process
1.  Pick a condition or disease
2.  Invent (discover) the vaccine construct & estimate the POS
3.  Test it pre-clinically
4.  Test it pre-clinically again…
5.  Revise the invention as needed
6.  Test it clinically:  Phase I
7.  Manufacture a large amount of the vaccine
8.  Test it clinically: Phase II  (POC)
9.  Test it clinically: Phase III  (& again…)
10. Apply for and receive regulatory approval
• Approved, on the market, and then… more follow-up observation: for any rare and/or long-
term side-effects, vaccine effectiveness.
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Development & Testing of a 
DNA-based COVID-19 Vaccine
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Background: Coronaviruses Pathogenic to Humans
• The first coronaviruses were 
discovered by Scottish 
virologist June Almeida in 
1966 (published in 1967):
• 7 are known to be pathogenic in humans:
-- 4 of those viruses can cause the common cold:    
229E      NL63     OC43     HKU1
-- The other 3 can cause much more serious disease:
- SARS-CoV   (SARS):     International epidemic 2003 with spread to more than 29 countries 
among 4 continents; sickened 8,098 & killed 774 people worldwide & cost an estimated US $40 
billion worldwide; virus was eliminated via great public health & medical work
- MERS-CoV    (MERS):   Presently endemic in Saudi Arabia etc. – occasional                  
nosocomial outbreaks; as of Jan. 2020 has sickened 2,519 & killed 866 people worldwide
- SARS-CoV-2  (COVID-19):   Present pandemic -- at least 300,000 dead, likely dozens of 
millions sickened, and perhaps 50 to 100 million infected worldwide so far…
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Background: Inovio DNA Medicines -- Immunotherapy and 
Vaccine Design & Administration Process
INOVIO DNA medicines are 
designed to power a patient’s 
immune system to generate 
functional antibodies and 
killer T cells in vivo, with 
intent to fight cancer and 
infectious disease
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Background: Inovio DNA Medicines -- Immunotherapy and 
Vaccine Design & Administration Process, cont’d.
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INO-4800 Inovio DNA Vaccine to Prevent COVID-19: Vaccine 
Design & Construction
• Antigen Target: the SARS-CoV-2 
Spike Protein (aka S protein)
• S protein genetic sequences of 
SARS-CoV-2 -- obtained from sequences internationally 
published/shared by the Chinese discoverers of the new virus
• Optimized DNA sequence of that protein was created using 
Inovio’s proprietary in silico Gene Optimization Algorithm
• DNA sequence cloned into expression vector plasmids
• Plasmids are produced/manufactured in E. coli bacteria cultures
• Preliminary testing in small animal models showed strong 
immune responses
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Inovio’s COVID-19 Investigational DNA Vaccine 
(INO-4800): Manuscript accepted for publication
This full non-published, non-peer-reviewed manuscript is posted at:
https://www.researchsquare.com/article/rs-16261/v1
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Phase I Clinical Trial:  Begun April 3-6, 2020
• Title: Phase 1 Open-label Study to Evaluate the Safety, 
Tolerability and Immunogenicity of INO-4800, a Prophylactic 
Vaccine Against SARS-CoV-2, Administered Intradermally 
Followed by Electroporation in Healthy Volunteers
• Enrollment estimated:  40 participants, age 18 to 50 years
• Groups:  two, one to receive one vaccine dose and the second 
to receive two vaccine doses (4 weeks apart)
• Funding:  Coalition for Epidemic 
Preparedness Innovations (CEPI)
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Timeline of COVID-19 detection, emergence of the SARS-
CoV-2 virus, & Inovio’s rapid vaccine R & D
• Dec. 30, 2019:  First ProMED posting of a small cluster of pneumonia cases of unknown cause in Wuhan, China – I see that while on winter 
holidays vacation & start following reports on progress of the cluster
• Dec. 31 & Jan. 1, 2020:  China informs the WHO of the cluster, & the WHO announces this
• Jan. 6:  After seeing further reports of the growing cluster, I send an alert to colleagues of 59 reported cases in the cluster, that all tests for 
flu, SARS, & MERS result negative, & that we must watch this
• Jan. 8:  Chinese scientists announce that a new virus has been isolated from pneumonia cases in Wuhan and that virus is a coronavirus
• Jan. 10, evening: Chinese scientists publically post the virus genetic sequence
• Jan. 11, early morning: I see that posting and notify our head of vaccine antigen design – Inovio (computer-aided) designs our DNA-based 
vaccine on paper in three hours; very soon grows lab-research quantities and begins initial pre-clinical testing
• Jan. 26:  Inovio receives a $9 million grant from CEPI to further develop our vaccine
• Jan. 23-Feb. 29:  Pre-clinical testing of the vaccine continues – immune responses seen in animal models
• Feb. 25:  Inovio submits manuscript to Nature Communications describing our vaccine design and preliminary pre-clinical testing results
• Mar. 12:  Inovio receives $5 million grant from the Bill & Melinda Gates Foundation to scale-up production of our intradermal 
delivery device for our COVID-19 DNA-based vaccine
• Mar 24: Inovio partners with Ology Bioservices to manufacture our vaccine with an $11.9 million US Dept. of Defense grant
• April 3-6:  Inovio initiates phase I human trial (83 days from vaccine design!) – Interim results 
expected in June 2020
• Feb – Present:  Efficacy trial design work…
• Summer 2020:  Pending FDA approval, start of the Inovio vaccine phase 2/3 efficacy trial
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How epidemiology is involved in the 
pharma R&D process for vaccines
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Epidemiology in Vaccines R & D: Overview
• Infection/Disease selection via public health and medical 
burden assessment
• Vaccine construct advisement – antigens, pathogenicity, and 
related burden
• Clinical trials design & planning: populations, locations, 
outcomes/endpoints selection, etc.
• Regulatory filings contributions (e.g. pediatric investigation 
plans)
• Clinical trial efficacy and safety results assessment






Therapeutic Testing:  Gold Standard & a Hypothetical 
Example
• The gold standard test of safety & efficacy of a therapy (& for a prophylactic vaccine also) is the 
randomized, double-blind, controlled clinical trial (RCT)
• This design helps to ensure that there is enough certainty in the results to allow regulatory 
approval
• A placebo is often but not always used as the control – the below example uses a placebo vs. 
the drug being tested in comparing overall mortality as an endpoint
• Hypothetical example:
--Disease “X” has a background case fatality rate/ratio (CFR): 0.5%
--Therapy “Z” (drug) is tested on 2,000 pts with disease X in an RCT with the following results:
Z (drug) arm CFR, 1,000 patients =  2 pts die attributed to disease “X” 
Placebo arm CFR, 1,000 patients =  5 pts die attributed to “X”
Therefore, summary efficacy result of the disease X-specific CFR by trial “arm” (patient group):
Z drug arm =    0.2%
Placebo arm =  0.5%
The drug works (albeit somewhat)!?  Right?
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Therapeutic Testing:  Gold Standard & a Hypothetical 
Example, cont’d.
• But, then we review the safety data of the trial and find:
-- In the drug “Z” arm, other 6 pts die of a serious adverse event (SAE) 
directly attributed to drug “Z” even as or after all 6 recovered from disease “X”,
--no patients die of adverse events directly attributed to the placebo 
(normal/physiologic saline)
Therefore, the summary result of the overall CFR by trial arm:
Z drug arm, 8 patients die of disease X OR an SAE  =   0.8%
Placebo arm, 5 patients die of disease X OR an SAE =  0.5%
• Conclusion: the drug works somewhat in directly preventing death due to disease 
“X” -- but does so at the cost of directly killing more pts than it saves from dying of 
disease “X”
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Some of the Great Vaccinologists in History
• Jonas Salk
Which vaccine did they 
each develop and test?...
• Albert Sabin




Some of the Great Vaccinologists in History – are even from, 
worked, or even still work in Philadelphia!
• Maurice Hilleman (Merck & Co., Inc.) – developed 
more than 40 vaccines, including many on the market 
today;  probably the single greatest vaccinologist in 
history (of anywhere), in terms of the number and 
type of vaccines developed and the collective 
number of disease prevented and lives saved (the 
former probably many hundreds of millions and the 
latter probably many tens or a few hundred million)
http://www.merck.com/about/featured-stories/vaccine-pioneers.html
• Stanley Plotkin (Wistar Institute, & Inovio Scientific 
Advisory Board) – developed many vaccines, 
including for rubella (German measles) and 
experimental vaccines including against rabies with 
Paul Offit…
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Some of the Great Vaccinologists in History – are even from, 
worked, or even still work in Philadelphia!  (cont’d.)
• Paul Offit (Director of the Vaccine Education Center 
at the Children’s Hospital of Philadelphia; is the Maurice
R. Hilleman Professor of Vaccinology and Professor of 
Pediatrics, Univ. of Pennsylvania); Co-invented the 
rotavirus vaccine, which saves lives of many babies 
around the world every day 
• David Weiner (Wistar Institute, Inovio co-founder); 
Founded the field of DNA vaccines
• Vaccinologists of the future…you?
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A Quiz




It – THEY, were the Ebola fighters!
They helped stop the spread of Ebola virus in the epidemic in 
West Africa
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How you can help (volunteer and/or work for pay) to mitigate 
the COVID-19 pandemic
Initiative, Program, or 
General Name Short Description Sponsor Organization Contact Info.
Contact Tracing & other 
temporary support jobs
Assist Federal, State, & Local Health 
Department Contact and Follow-up Direct, 
Secondary, & Tertiary Contacts of Lab-
Confirmed COVID-19 Diagnosed Persons
--US CDC
--Your State Health Dept.





COVID-19 Citizen Science 
(CCS) Study
Participate in a study as a research subject --
help researchers gain insight into how the 
virus is spreading and identify ways to 
predict and reduce the number of new 
infections
Univ. California, San Francisco (UCSF), 
American Lung Association, and 
Northwestern Medicine
https://eureka.app.link/covid19
if prompted, enter the study key: covid) or by texting “COVID” to 
41411
COVID-19 Symptom Tracker Report your symptoms once per day & get a 
daily estimate of COVID-19 in your area 
Massachusetts General Hospital, 
Harvard Univ., King’s College London, 
Stanford Univ., & ZOE
https://covid.joinzoe.com/us
Help design a treatment Assist in design of candidate proteins etc. to 
screen for possible treatments
Foldit https://fold.it/
Multiple options Clearing house for multiple resources Citizen Science https://www.citizenscience.org/covid-19/









Learning, game, & etc. resources, including 
“SimPandemicTM”
Science Buddies https://www.sciencebuddies.org/science-projects/coronavirus-
COVID-19
